Achievement of Goal Resting Heart Rate on B-blockers in Patients With Stable Angina and Hypertension (Athena)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01321242
First received: March 22, 2011
Last updated: May 31, 2012
Last verified: May 2012

March 22, 2011
May 31, 2012
April 2011
August 2011   (final data collection date for primary outcome measure)
Establish the proportion of patients with stable angina and hypertension on beta-blockers reaching the resting HR goals according to ACC/AHA/ACP-ASIM* Guidelines [ Time Frame: 1 visit within 5 month ] [ Designated as safety issue: No ]
*American College of Cardiology (ACC)/American Heart Association (AHA)/American College of Physicians (ACP-ASIM)
Same as current
Complete list of historical versions of study NCT01321242 on ClinicalTrials.gov Archive Site
  • Establish the mean dose of each beta-blocker in patients who achieved and not achieved resting HR goals [ Time Frame: 1 visit within 5 month ] [ Designated as safety issue: No ]
  • Compare quality of life in patients who achieved and non achieved resting HR goals [ Time Frame: 1 visit within 5 month ] [ Designated as safety issue: No ]
  • To estimate the correlation between achievement of resting HR goals according to ACC/AHA/ACP-ASIM Guidelines for the management of patients [ Time Frame: 1 visits within 5 month ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Achievement of Goal Resting Heart Rate on B-blockers in Patients With Stable Angina and Hypertension
Observational Non-interventional Study - Epidemiological Survey "AchievemenT of Goal Resting HEart Rate on Beta-blockers in Patients With Stable angiNA and Hypertension in Routine Practice"

This is a multicenter survey of Russian data on target heart rate achievement in patients with stable angina and arterial hypertension who are currently treated with beta-blockers for at least 2 months and with no dose change for a minimum of 4 weeks

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Clinical practice

  • Stable Angina
  • Hypertension
Not Provided
  • achieving resting HR goals
    Patient population will be comprised of typical for cardiological practice sample of patients with Coronary Heart Disease and arterial hypertension administered beta-blockers, subjects achieving resting HR goals, according to ACC/AHA/ACP-ASIM Guidelines
  • non-achieving HR goals
    Patient population will be comprised of typical for cardiological practice sample of patients with Coronary Heart Disease and arterial hypertension administered beta-blockers, subjects non-achieving HR goals, according to ACC/AHA/ACP-ASIM Guidelines
Kobalava Z, Khomitskaya Y, Kiyakbaev G; ATHENA trial investigators. AchievemenT of target resting HEart rate on beta-blockers in patients with stable angiNA and hypertension (ATHENA) in routine clinical practice in Russia. Curr Med Res Opin. 2014 May;30(5):805-11. doi: 10.1185/03007995.2013.874993. Epub 2014 Jan 17.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
400
August 2011
August 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Stable angina I-III class by the Canadian Cardiovascular Society Classification and concomitant primary hypertension
  • Subject is on beta-blockers treatment for at least 2 months prior to inclusion into survey, with no dose change for a minimum of 4 weeks

Exclusion Criteria:

  • Use of phenylalkylamine and benzothiazepine calcium channel blockers
  • Hemodynamic significant mitral and aortic valve disease
  • Acute myocardial infarction and unstable angina within 3 months before enrolment
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Russian Federation
 
NCT01321242
NIS-CRU-ATC-2011/1
No
AstraZeneca
AstraZeneca
Not Provided
Study Director: Alexey Stepanov AstraZeneca
Principal Investigator: Z.D. Kobalava The Russian Peoples' Friendship University, Municipal Clinical Hospital #64
AstraZeneca
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP